231 related articles for article (PubMed ID: 35843496)
1. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
[TBL] [Abstract][Full Text] [Related]
2. Inactivated vaccine Covaxin/BBV152: A systematic review.
Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
Front Immunol; 2022; 13():863162. PubMed ID: 36016940
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
[TBL] [Abstract][Full Text] [Related]
4. Covid-19 Vaccines Available in India.
Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
[TBL] [Abstract][Full Text] [Related]
5. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case-control study.
Bhattacharya D; Kanungo S; Palo SK; Kshatri JS; Pattnaik M; Ghosal S; Mohapatra P; Rao CM; Sahoo A; Mishra RP; Mishra S; Mohanta AR; Doley C; Pati S
Front Public Health; 2022; 10():1041586. PubMed ID: 36684990
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
[TBL] [Abstract][Full Text] [Related]
14. Impact of prior vaccination with Covishield
Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
[TBL] [Abstract][Full Text] [Related]
15. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
[TBL] [Abstract][Full Text] [Related]
16. First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.
Tsundue T; Namdon T; Tsewang T; Topgyal S; Dolma T; Lhadon D; Choetso T; Woesal T; Yangkyi T; Gupta A; Peters D; Paster Z; Phunkyi D; Sadutshang TD; Chaisson RE; Dorjee K
BMJ Glob Health; 2022 May; 7(5):. PubMed ID: 35609920
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study.
Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M
Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.
Das S; Kar SS; Samanta S; Banerjee J; Giri B; Dash SK
Immunol Res; 2022 Jun; 70(3):289-315. PubMed ID: 35192185
[TBL] [Abstract][Full Text] [Related]
19. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S
JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
